Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc > Open Label?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(12)
•••
Comment by canadapieton Dec 07, 2022 11:49am
136 Views
Post# 35156455

RE:RE:RE:RE:RE:Open Label?

RE:RE:RE:RE:RE:Open Label?
Can you elaborate us what the "real value" of TH is?????

We know they have 2 selling products
We know they have dollar devouring r & d 
We know they have no partnership
We know they have HUGE debt
We know insiders don't believe either in Th
We know they lied (efficacy seen, "key",....)
....

Thx 


palinc2000 - (12/7/2022 11:30:12 AM)
RE:RE:RE:RE:Open Label?

Nice to read a rational post! This MB is being flooded by panicky ignorant amateurish unsophisticated shareholders.Panick attacks serve no purpose and only compound the problem
We are all very disappointed with the SP but the real question is "Does the current SP reflect the fair value  of the company "

The pool of sellers should be drying up soon .... Cool heads should prevail with an upward correction to the SP ...This is my take but I know that others may have a different opinion ..... so be it!!
 


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities